Navigation Links
CREON(R) (pancrelipase) Delayed-Release Capsules Improves Digestive Outcomes In Adults With Chronic Pancreatitis
Date:10/26/2009

CFA) as compared to the placebo group. CFA is calculated based on measures of fat ingestion and fat excretion; assessing the CFA of a patient is another way to measure the absorption of fat as a percentage of fat intake in patients being tested for EPI. The primary efficacy endpoint was the change in CFA from baseline to the end of the double-blind treatment period. The CFA improved by 32.1% in the CREON® group compared to 8.8% in the placebo group, representing a statistically significant difference between CREON® and placebo (P<0.0001).

"These data add to the growing body of evidence supporting the efficacy and safety profile of CREON® across multiple conditions while also providing clarity around the appropriate dosing of pancreatic enzyme replacement therapy in these patients," said Elizabeth M. Mutisya, M.D., Vice President of U.S. Medical Affairs and Chief Medical Officer at Solvay Pharmaceuticals, Inc. "These CREON® study results are encouraging as dosing of pancreatic enzymes for patients with EPI due to CP or pancreatic surgery has not previously been well defined."

Study Details

The double-blind, randomized, placebo-controlled, two-arm, parallel-group study conducted in the United States, Eastern and Central Europe, examined the efficacy and safety of CREON® 12,000-lipase unit capsules in 52 adults aged 18 years or older with EPI due to CP or pancreatic surgery. Patients were randomized to receive CREON® 12,000-lipase unit capsules at a dose of 72,000 lipase units per main meal and 36,000 lipase units per snack or matching placebo. EPI was confirmed in all subjects through direct pancreatic function testing such as, secretin tests or fecal elastase (< 100 micrograms/g), 72-hour fecal fat determination (> 15 g/day) or pancreatectomy more than 180 days prior to study enrollment.

Upon analysis of the primary efficacy results, the mean CFA increased by 32.1% in t
'/>"/>

SOURCE Solvay Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Results Published In Journal of Cystic Fibrosis Confirm CREON(R) (pancrelipase) Delayed-Release Capsules Improves Fat Absorption in Patients With Cystic Fibrosis
2. CREON(R) (pancrelipase) Delayed-Release Capsules Improves Absorption of Fat in Young Children With Cystic Fibrosis
3. Procter & Gamble Pharmaceuticals Launches Asacol(R) HD (mesalamine) Delayed-Release Tablets
4. Aptivus(R) (tipranavir) Capsules Granted Full Approval by the U.S. FDA
5. GSK Receives Approval for HYCAMTIN(R) (topotecan) Capsules for the Treatment of Relapsed Small Cell Lung Cancer
6. Alpharma Announces Positive Results From Pivotal Phase III Efficacy Trial on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) Capsules at the American Academy of Pain Management Annual Clinical Meeting
7. Roxane Laboratories, Inc. Updated Launch of Calcium Acetate Capsules, 667mg
8. Mylan Receives FDA Approval for Generic Version of Anticonvulsant Topamax(R) Sprinkle Capsules
9. Experimental Drug Ketasyn(TM) Improves Memory in Age-Associated Memory Impairment Study
10. First Osteoporosis Study in Hip Fracture Patients Finds Once-Yearly Reclast(R) Prevents Additional Fractures and Improves Survival
11. New England Journal of Medicine Study Shows ERBITUX(R) Improves Survival in Advanced Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... 2015 PTC Therapeutics, Inc. (NASDAQ: PTCT ... results for the second quarter ending June 30, 2015. ... across the organization.  We are excited to be near ... trial ever conducted with topline results expected in the ... Officer, PTC Therapeutics, Inc. "Translarna is now commercially available ...
(Date:7/30/2015)... 2015  Cleveland Clinic President Wael Barsoum , ... month that industry is compelled to adopt declining reimbursements ... efficiencies—and develop the transformational innovations -- required to thrive ... preceded by Doug Kohrs , past President and ... stressed that industry must add "episode of care," also ...
(Date:7/30/2015)... July 30, 2015 Future Market ... titled, "Continuous Glucose Monitoring Systems Market: Global Industry Analysis ... report, the global continuous glucose monitoring systems market was ... expected to reach US$ 788.4 Mn by 2020, registering ... to 2020. Global continuous glucose monitoring systems ...
Breaking Medicine Technology:PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 10Orthopaedic Surgery Reimbursement Shifts to Episode of Care 2Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 2Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 3Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 4
... issued the following update regarding the voluntary recall of AVEA® ... this action as a Class I recall. ... by the company and CareFusion is actively remediating the hardware ... parts manufactured between March 1, 2009 and June 30, 2011 ...
... Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... the company completed its previously announced acquisition of iNova, ... BofA Merrill Lynch and Baker & McKenzie ... About Valeant Pharmaceuticals International, Inc. ...
Cached Medicine Technology:CareFusion Provides Update on Previously Announced Ventilator Recall 2
(Date:7/31/2015)... ... 2015 , ... The 2015 New York Regional Conference on ... professionals, and researchers, covering a variety of topics related to mesothelioma and presented ... the Mesothelioma Applied Research Foundation and Memorial Sloan Kettering Cancer Center. , The ...
(Date:7/31/2015)... ... July 31, 2015 , ... “Engage: Don’t Just ... industry’s premier thought leadership symposiums, hosted by Massachusetts-based Harmony Healthcare International at ... attracts over 250 “C”-level executives, administrators, directors of nursing, rehabilitation managers and other ...
(Date:7/31/2015)... NY (PRWEB) , ... July 31, 2015 , ... The ... marijuana, on research projects that evaluate the potential of related, experimental treatments. The collaboration ... Department of Health to award Columbia Care one of five state licenses to produce ...
(Date:7/31/2015)... ... July 31, 2015 , ... Like nearly every other form of ... advanced, upgraded, made more effective and less intrusive and painful. Leading these advances ... Center. Dr. Loria currently stands as the only doctor in the United States ...
(Date:7/31/2015)... ... 31, 2015 , ... The Heart Fit Clinic has increased a patient's fitness ... rate of 150 beats versus 100 beats, this is a big deal," says Diamond ... life back to patients with heart disease," he adds. People with angina are able ...
Breaking Medicine News(10 mins):Health News:New York Area Mesothelioma Specialists to Present at Conference 2Health News:New York Area Mesothelioma Specialists to Present at Conference 3Health News:Harmony Healthcare International Announces Speaker Line-up for “HARMONY 2015” 2Health News:Harmony Healthcare International Announces Speaker Line-up for “HARMONY 2015” 3Health News:Mount Sinai to Collaborate with Columbia Care on Medical Marijuana Research 2Health News:Mount Sinai to Collaborate with Columbia Care on Medical Marijuana Research 3Health News:Loria Medical Penile Enlargement Center to Expand, Offering Practice Partnership to Doctors 2Health News:Heart Fit Clinic Helps Patient Increase Fitness Level with External Counterpulsation 2
... ... “Ten Best Staffing Firms to Work For,” published earlier this month in Staffing Industry ... ... research and analysts firm, surveys companies in the contingent staffing industry to determine the ...
... , WASHINGTON, Dec. 10 The following is ... Tobacco-Free Kids: , (Logo: http://www.newscom.com/cgi-bin/prnh/20080918/CFTFKLOGO ) , ... health and the public,s right to breathe clean air ... all restaurants and bars, smoke-free. Gov. Jennifer Granholm has ...
... tamoxifen can improve outcomes for postmenopausal breast cancer patients, according ... But a related study presented today at the 2009 San ... tumors can identify a subset of patients who may not ... Dr. Kathy Albain, of Loyola University Health System. Both ...
... ... Best Practices for Developing an Intelligent Portfolio , ... Austin, Texas (PRWEB) December 10, 2009 -- ... case study webinar discussing best practices for increasing the ROI of IT portfolios with ...
... well-resourced Global Fund for Education in 2010 will bring the world ... Dr. Paul Zeitz , WASHINGTON, Dec. 10 Today ... Universal Declaration of Human Rights which states (in Article 26): "Everyone ... least in the elementary and fundamental stages." , The ...
... DETROIT, Dec. 10 African-American political leaders, union members, ... 14th to create and implement a strategy to ... , "Detroit is leading the nation in murders, ... Horace Sheffield III, National Board Member and Michigan Chapter ...
Cached Medicine News:Health News:Jackson & Coker Ranks #3 among &#8220;Ten Best Staffing Firms to Work For&#8221; 2Health News:Jackson & Coker Ranks #3 among &#8220;Ten Best Staffing Firms to Work For&#8221; 3Health News:Jackson & Coker Ranks #3 among &#8220;Ten Best Staffing Firms to Work For&#8221; 4Health News:Approval of Michigan Smoke-Free Legislation is Historic Win for Health 2Health News:Approval of Michigan Smoke-Free Legislation is Historic Win for Health 3Health News:Definitive study confirms chemo benefit in postmenopausal breast cancer 2Health News:Definitive study confirms chemo benefit in postmenopausal breast cancer 3Health News:Planview and Carestream Health Discuss the Intelligent Portfolio on December 17 Webinar 2Health News:Planview and Carestream Health Discuss the Intelligent Portfolio on December 17 Webinar 3Health News:Human Rights Denied: Obama Leaves 75 Million Children Behind 2Health News:Black Community Unites Against HIV/AIDS Epidemic 2
Freer elevator, double end, 7 1/4", S/B....
... The Surgifoam* absorbable gelatin sponge, U.S.P. ... gelatin absorbable sponge intended for hemostatic ... surface. The sponge is off-white and ... speed to hemostasis, highly favorable surgeon ...
... absorbable gelatin sponge, U.S.P. is a ... sponge intended for hemostatic use by ... sponge is off-white and porous in ... hemostasis, highly favorable surgeon preference ratings ...
16 mm diameter curved probes with suture eyes just back of blunt ends. Stainless steel. Round knurled handle with polished finish. Overall length: 5.7 inches....
Medicine Products: